At ESMO Virtual Congress 2020, the first report of clinical responses in multiple solid tumour subtypes increases knowledge on safety of tumour-infiltrating lymphocyte-based adoptive cell therapy combined with immunotherapy.

Immunotherapy as second- and third-line treatment is effective in pre-treated malignant pleural mesothelioma

Presentations at ESMO Virtual Congress 2020 gave insights into the impact of COVID-19 on cancer management, cancer research and the healthcare professionals involved, which can help to prepare for future crises.

Study design still seems to be a major limitation to translate promising approaches in rare cancers, as negative trials presented at the ESMO Virtual Congress 2020 show.

Encouraging data from phase I and II studies in pre-treated adult patients but not in children where prognosis is poor.

Findings from early clinical trials at the ESMO Virtual Congress 2020 are encouraging for the use of precision medicine in adenoid cystic carcinoma and salivary gland carcinoma

In the LEAP-004 study presented at the ESMO Virtual Congress 2020, ORR is encouraging but survival results are difficult to interpret.

ICON8 trial final analysis confirms results of the previously published progression-free survival analysis

Understanding the impact of the patients’ sex on clinical outcomes to treatment with immunotherapy might add another piece to the puzzle of the most effective way to use checkpoint inhibitors.

Encouraging early data suggests PD-1 blockade is also effective in other advanced non-melanoma skin cancers such as advanced basal cell carcinoma.